MLYS insider ownership: who sold, why, and what they still hold

What stands out

Three insiders sold $16.0M with no disclosed plan: Jon Congleton ($9.1M), Adam Levy ($5.4M) and Alexander Gold ($1.6M). The filings don't state a reason.Jon Congleton: largest such sale, Nov 11, 2025 · Adam Levy: largest such sale, Nov 11, 2025 · Alexander Gold: largest such sale, Nov 13, 2025

Shareholders represented on the board by Brian Slingsby, not part of management, sold $46.4M of stock.Largest sale, Nov 20, 2025

A share of stake is shown for 0 of the 6 officers and directors who sold. 11 are left out

Left out: Jon Congleton, Srinivas Akkaraju, Adam Levy, David Rodman, Derek DiRocco, Eric Warren, Brian Slingsby, Glenn Sblendorio, Daphne Karydas, Alexander Gold and James Ferguson III (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Jon Congleton

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$16.2M44% planned 56% no plan disclosed

David Rodman

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$14.4MDisclosed plan

Adam Levy

CFO and Secretary

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.7M6% planned 94% no plan disclosed

Eric Warren

Chief Commercial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.3MDisclosed plan

Alexander Gold

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.6MNo plan disclosed

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 30, 2026Jon Congleton sold 75K shares ($1.9M) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Jon Congleton Chief Executive Officer, Director	75,000	$25.46	n/a	n/a	Sep 30, 2026	Oct 2, 2026

Sep 21, 2026Eric Warren sold 7.4K shares ($209K) under a disclosed trading plan. 7.4K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Eric Warren Chief Commercial Officer	7,438	$28.12	n/a	n/a	Sep 21, 2026	Sep 22, 2026

Sep 15, 2026Daphne Karydas sold 3K shares ($86K) under a disclosed trading plan. 3K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Daphne Karydas Director	3,000	$28.58	n/a	n/a	Sep 15, 2026	Sep 17, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

Brian Slingsby (for the outside shareholder represented on the board) sold $46.4M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Mineralys Therapeutics, Inc. CEO selling stock?

Yes. Jon Congleton sold 468K shares ($16.2M) in the past 12 months, 44% of it under a trading plan disclosed in the filings.

Why are Mineralys Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 60% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 40% had no disclosed plan. A trading plan schedules sales in advance.

Are any Mineralys Therapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Jon Congleton Chief Executive Officer, Director	$16.2M 468K shares	Not confirmed share of stake is being verified. Why	44% under a disclosed plan 56% no plan disclosed
David Rodman Chief Medical Officer	$14.4M 441K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Adam Levy CFO and Secretary	$5.7M 130K shares	Not confirmed share of stake is being verified. Why	6% under a disclosed plan 94% no plan disclosed
Eric Warren Chief Commercial Officer	$3.3M 126K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Alexander Gold Director	$1.6M 35K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Daphne Karydas Director	$926K 24K shares	Not confirmed share of stake is being verified. Why	25% under a disclosed plan 75% no plan disclosed

Board members representing outside shareholders, reported separately: Brian Slingsby (the shareholder sold $46.4M), Srinivas Akkaraju. Details

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 11 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Jon Congleton

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jon Congleton are complete.

Chief Executive Officer, Director

n/a

−468K

n/a

Vesting, gifts, unvested awards and holding lines for Jon Congleton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jon Congleton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
425,000	$14.25	Feb 13, 2034	$4.8M
570,000	$10.20	Feb 13, 2035	$8.7M
187,900	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Srinivas Akkaraju

Director

n/a

Vesting, gifts, unvested awards and holding lines for Srinivas Akkaraju

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Srinivas Akkaraju are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,000	$12.52	May 22, 2034	$285K
32,900	$10.20	Feb 13, 2035	$502K
8,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Adam Levy

CFO and Secretary

n/a

−130K

n/a

Vesting, gifts, unvested awards and holding lines for Adam Levy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adam Levy are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
200,000	$14.25	Feb 13, 2034	$2.2M
170,000	$10.20	Feb 13, 2035	$2.6M
20,662	$16.00	Feb 9, 2033	$196K
4,888	$15.44	Mar 17, 2033	$49K
91,592	$14.25	Feb 13, 2034	$1.0M
135,674	$10.20	Feb 13, 2035	$2.1M
53,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

David Rodman

Chief Medical Officer

n/a

−441K

n/a

Vesting, gifts, unvested awards and holding lines for David Rodman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Rodman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,024	$16.00	Feb 9, 2033	$123K
3,334	$15.44	Mar 17, 2033	$33K
79,167	$14.25	Feb 13, 2034	$888K
109,792	$10.20	Feb 13, 2035	$1.7M
51,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Derek DiRocco

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Derek DiRocco are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Derek DiRocco

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Derek DiRocco are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,000	$12.52	May 22, 2034	$285K
32,900	$10.20	Feb 13, 2035	$502K
8,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Eric Warren

Chief Commercial Officer

n/a

−126K

n/a

Vesting, gifts, unvested awards and holding lines for Eric Warren

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Warren are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
230,563	$13.24	Apr 21, 2035	$2.8M
51,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Brian Slingsby

Director

n/a

Vesting, gifts, unvested awards and holding lines for Brian Slingsby

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Slingsby are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Glenn Sblendorio

Director

n/a

Vesting, gifts, unvested awards and holding lines for Glenn Sblendorio

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Glenn Sblendorio are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,000	$12.52	May 22, 2034	$285K
32,900	$10.20	Feb 13, 2035	$502K
8,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Daphne Karydas

Director

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Daphne Karydas

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daphne Karydas are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,000	$12.02	Sep 13, 2033	$470K
22,000	$12.52	May 22, 2034	$285K
17,900	$10.20	Feb 13, 2035	$273K
8,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Alexander Gold

Director

n/a

−35K

n/a

Vesting, gifts, unvested awards and holding lines for Alexander Gold

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alexander Gold are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,000	$12.69	Jun 13, 2034	$434K
8,225	$10.20	Feb 13, 2035	$126K
8,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

James Ferguson III

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for James Ferguson III

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Ferguson III are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
135,000	$27.38	Aug 10, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Holdings and share of stake for Mineralys Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$42.1M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $42.1M across 1,224,318 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $25.4M · 60%

40%

The lighter segment is sales with no plan disclosed in the filing ($16.7M), including tax-related sales outside a plan.

No plan disclosed · $16.7M

Sales with no 10b5-1 plan and no tax reference in the filing. $9.1M of it is Jon Congleton. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Jon Congleton, Nov 11, 2025

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Jon Congleton Chief Executive Officer, Director	468K	$16.2M	44%	38%	Nov 11, 2025 to Sep 30, 2026
David Rodman Chief Medical Officer	441K	$14.4M	100%	34%	Oct 15, 2025 to Aug 10, 2026
Adam Levy CFO and Secretary	130K	$5.7M	6%	14%	Nov 11, 2025 to Jan 12, 2026
Eric Warren Chief Commercial Officer	126K	$3.3M	100%	8%	Jun 26, 2026 to Sep 21, 2026
Alexander Gold Director	35K	$1.6M	0%	4%	Nov 11, 2025 to Nov 13, 2025
Daphne Karydas Director	24K	$926K	25%	2%	Nov 13, 2025 to Sep 15, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$446K	$446K	$0	$0
Nov 2025	$16.7M	$0	$0	$16.7M
Dec 2025	$0	$0	$0	$0
Jan 2026	$11.1M	$11.1M	$0	$0
Feb 2026	$647K	$647K	$0	$0
Mar 2026	$2.7M	$2.7M	$0	$0
Apr 2026	$1.0M	$1.0M	$0	$0
May 2026	$664K	$664K	$0	$0
Jun 2026	$5.3M	$5.3M	$0	$0
Jul 2026	$1.1M	$1.1M	$0	$0
Aug 2026	$252K	$252K	$0	$0
Sep 2026	$2.2M	$2.2M	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (2)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Brian Slingsby

Director

n/a

−1.10M

n/a

Vesting, gifts, unvested awards and holding lines for Brian Slingsby

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Slingsby are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,000	$12.52	May 22, 2034	$285K
32,900	$10.20	Feb 13, 2035	$502K
8,300	$28.06	Feb 19, 2036	$0

Estimate: options held × ($25.46 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Srinivas Akkaraju

Director

n/a

Vesting, gifts, unvested awards and holding lines for Srinivas Akkaraju

0gifted (net of own trusts)

Known gaps and uncertainty11 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Mineralys Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology176 filings on record, 59 filed in the 12-month period, and how we read them

All 176 Forms 3, 4 and 5 on record for Mineralys Therapeutics, Inc. (SEC CIK 1933414), filed from Feb 9, 2023 to Oct 2, 2026; 59 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (4)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Olivier Litzka	May 23, 2024	No balance on record
Takeshi Takahashi	Jul 14, 2023	No balance on record
HBM Healthcare Investments (Cayman) Ltd.	Feb 16, 2023	3,218,106 shares, last reported balance as of Feb 14, 2023
Alexander Asam	Feb 13, 2023	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Mineralys Therapeutics, Inc. insiders sold $42.1M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Mineralys Therapeutics, Inc. CEO selling stock?

Why are Mineralys Therapeutics, Inc. insiders selling?

Are any Mineralys Therapeutics, Inc. insiders buying?

The evidence

No plan disclosed · $16.7M

Sales by month